Back

Clinical and peri procedural outcomes using reduced dose prasugrel vs standard dose ticagrelor in elderly patients of acute coronary syndrome undergoing PCI

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Bleeding and antiplatelet strategies in acute coronary syndromes Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Arshad Nazir

Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow (India)

7 More presentations in this session

Presentation thumbnail
Temporal trends in major bleeding after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction from 2003 to 2017: the Western Denmark Heart Registry
Doctor P. Thrane (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Thirty days clinical outcomes following stent implantation with aspirin-free prasugrel monotherapy in non-ST segment elevation myocardial infarction. Interim report from ASET-Japan pilot study
Doctor K. Miyashita (Galway, IE)
Abstract Slides Video
Presentation thumbnail
Ticagrelor vs. clopidogrel in ST elevation myocardial infarction patients with hemoglobin > 160
Doctor T. Gu (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Safety and effectiveness of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study
Doctor F. Wenzl (Zurich, CH) Doctor F. Bruno (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Association of P2Y12 inhibitor pretreatment strategy with short and long term ischemic and bleeding outcomes in NSTE-ACS patients
Doctor K. Keskin (Hakkari, TR) Associate Professor A. Calik (Istanbul, TR)
Abstract Slides Video

Access the full session

Session thumbnail
Bleeding and antiplatelet strategies in acute coronary syndromes

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Ticagrelor vs. clopidogrel in elderly patients following acute myocardial infarction: a multicenter international analysis
thumbnail
Congress Presentation
Choosing the most effective and safest P2Y12 Inhibitor for use in >70-year-old acute coronary syndrome patients: a network meta-analysis
thumbnail
Congress Presentation
The real-world safety of ticagrelor among older adults (above 75 years): a pharmacovigilance study from the FDA data

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources